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Abstract
Peroxisome proliferator-activated receptor (PPAR) delta is an important regulator of fatty acid (FA) metabolism.
Angiopoietin-like 4 (Angptl4), a multifunctional protein, is one of the major targets of PPAR delta in skeletal muscle cells.
Here we investigated the regulation of Angptl4 and its role in mediating PPAR delta functions using human, rat and mouse
myotubes. Expression of Angptl4 was upregulated during myotubes differentiation and by oleic acid, insulin and PPAR delta
agonist GW501516. Treatment with GW501516 or Angptl4 overexpression inhibited both lipoprotein lipase (LPL) activity
and LPL-dependent uptake of FAs whereas uptake of BSA-bound FAs was not affected by either treatment. Activation of
retinoic X receptor (RXR), PPAR delta functional partner, using bexarotene upregulated Angptl4 expression and inhibited
LPL activity in a PPAR delta dependent fashion. Silencing of Angptl4 blocked the effect of GW501516 and bexarotene on LPL
activity. Treatment with GW501516 but not Angptl4 overexpression significantly increased palmitate oxidation.
Furthermore, Angptl4 overexpression did not affect the capacity of GW501516 to increase palmitate oxidation. Basal and
insulin stimulated glucose uptake, glycogen synthesis and glucose oxidation were not significantly modulated by Angptl4
overexpression. Our findings suggest that FAs-PPARdelta/RXR-Angptl4 axis controls the LPL-dependent uptake of FAs in
myotubes, whereas the effect of PPAR delta activation on beta-oxidation is independent of Angptl4.
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Introduction
Skeletal muscle is the main site for burning excess calories when
exercised hence, it plays a key role in the prevention and
management of metabolic diseases such as type 2 diabetes. In our
modern society there is a chronic positive energy balance due to
overnutrition and inactivity. An oversupply of skeletal muscle with
fatty acids (FAs), exceeding its oxidative capacity, results in
accumulation of intramyocellular lipids. Increased ectopic lipid
deposition in liver and skeletal muscle is associated with increased
concentrations of active lipid metabolites such as diacylglycerols
and ceramides, impaired insulin signaling, and thus plays a major
role in lipid-induced insulin resistance of obesity and type 2
diabetes [1]. A deeper understanding of the mechanisms
regulating FA uptake in skeletal muscle can potentially be used
to ameliorate perturbations in systemic lipid balance and insulin
sensitivity.
Skeletal muscle, as well as other tissues, obtain FAs either via
lipoprotein lipase (LPL, EC 3.1.1.34)-mediated hydrolysis of
lipoprotein triglycerides or from unesterified FAs bound to
albumin [2]. Although it is difficult to discern which is the major
pathway for FA uptake, the LPL-mediated uptake has the
advantage of being tightly regulated in a tissue specific manner
independent of albumin-bound FAs. Stored FAs are released from
adipose tissue by intracellular lipolysis and are rapidly taken up by
the liver, esterified to triglycerides, packed in lipoproteins and
secreted as VLDL. Dietary FAs are absorbed by enterocytes,
packed and secreted into the circulation as chylomicrons. Thus,
.90% of circulating FAs are contained within VLDL and
chylomicron particles and delivered to skeletal muscle and heart
(oxidation) or adipose tissue (storage) by LPL-catalyzed lipolysis
[2]. LPL is produced in parenchymal cells of these tissues, and it is
transported and bound by glycosylphosphatidylinositol-anchored
high density lipoprotein-binding protein 1 (GPIHBP1) to the
luminal side of the capillary endothelium where it exerts its main
function [3,4].
Peroxisome proliferator-activated receptor (PPAR) d is the main
PPAR isoform in skeletal muscle and an important regulator of FA
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metabolism [5–10]. Due to their capacity to enhance FA
catabolism specific PPARd agonists, such as GW501516, are
promising drugs to treat metabolic diseases such as type 2 diabetes.
Interestingly, one major target of PPARd in skeletal muscle is
angiopoietin-like 4 (Angptl4) [11], a potent inhibitor of LPL
[12,13]. In addition, Angptl4 is a modulator of adiposity by
enhancing intracellular lipolysis in adipocytes [14–16].
Here we describe the mechanism by which PPARd activation
by FAs upregulates Angptl4 and inhibits LPL activity and LPL-
mediated FA uptake in myotubes. Since Angptl4 is a multifunc-
tional protein we also tested its effect on FA oxidation and glucose
metabolism.
Materials and Methods
Cell Culture
Muscle samples for primary human myoblast cultures were
obtained from surgical open muscle biopsies. Biopsies were taken
from 6 nondiabetic men (BMI 25.164.2 kg/m2 (mean 6 SD), age
5467 yrs). Satellite cells were isolated, myoblasts proliferated and
differentiated into myotubes as previously described [17]. Written
informed consent was obtained from the subjects and the study
was approved by the Ethical Committee of Department of
Medicine, Helsinki University Central Hospital. All experiments
were performed in accordance with the principles of the
Declaration of Helsinki, as revised in 2000. L6 (ATCC, CRL-
1458) and C2C12 (ATCC, CRL-1772) myoblast cell lines were
maintained in high glucose Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) fetal calf serum, 10 mM
HEPES, pH 7.4, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (full growth medium). Details about C2C12 myoblasts
stably transfected with human LPL (C2/LPL) were described
previously [18]. When cells reached 60–80% confluence full
growth medium was replaced with DMEM containing 2% horse
serum (differentiation medium) to induce the differentiation of
proliferating myoblasts. Differentiation medium was replaced
every day for 6–7 days until multinucleated myotubes were
formed. All experiments have been performed in differentiation
medium unless otherwise specified or required by previously
described protocols. In experiments where BSA-bound oleic acid
(OA-BSA) was used defatted BSA at the same concentration was
added in control samples and combined with other treatments.
Conventional light microscopy images were collected during the
differentiation process. Human myotubes were fixed and stained
with hematoxylin before image collection. The viability and
attachment of the cells were carefully evaluated by light
microscopy and protein measurements and no cytotoxic effects
could be observed throughout the study.
Preparation and in vitro delivery of recombinant adeno-
associated viruses (AAV)
Human Angptl4 (hAngptl4) and serum albumin (HSA) cDNAs
were cloned into blunted MluI and NheI restriction sites of the
psubCMV-WPRE recombinant AAV expression vector [19]. The
AAVs serotype 2 and 9 (AAV2 and AAV9) were produced as
described previously [20]. AAV2 was more efficient in transducing
cells in vitro compared to AAV9 whereas the opposite was true in
vivo. Virus transduction was performed on day four of differen-
tiation using Angptl4-AAV2 or HSA-AAV2 at a concentration of
166109 virus genomes per ml. Experiments were performed 48 or
72 hours post-infection.
Quantitation of Angptl4 by ELISA
The development and validation of hAngptl4 ELISA was
published previously [21]. Quantification of secreted hAngptl4 was
performed in medium (with or without serum) after a twofold
dilution with the ELISA dilution buffer [21]. To measure cell
Figure 1. Angptl4 mRNA and protein levels are increased during differentiation of myotubes. Proliferative myoblasts from human (a)
and mouse (d) C2/LPL were differentiated in multinucleated (b, inset) myotubes (b, human and e, mouse) and visualized using conventional light
microscopy. (c) Secretion of Angptl4 was quantified by ELISA from day 2 to day 7 of differentiation and adjusted for protein content in cells derived
from three men. (f) Angptl4 and PPARd mRNA levels were measured by real time PCR during differentiation of C2/LPL myoblasts, n = 4. Values are
expressed as fold increase relative to day two of differentiation and normalized to human b-actin or mouse 36B4 mRNA levels. Results are expressed
as mean 6 SEM, (c) n = 3 and (f) n = 4. Scale bar: 50 mm. *p,0.05 as compared with day 2 using Repeated Measures ANOVA with Dunnett’s post test.
doi:10.1371/journal.pone.0046212.g001
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associated hAngptl4 myotubes were lysed in RIPA buffer [50 mM
Tris, pH 8.0, 150 mM NaCl, 1% (v/v) NP-40, 0.5% (v/v) sodium
deoxycholate, 0.1% SDS] supplemented with complete mini
EDTA-free protease inhibitor cocktail (Roche). Cell lysate was
diluted to a minimum of four fold without significant effect on the
ELISA measurements.
Figure 2. Angptl4 protein expression is increased by free fatty acids and insulin in human myotubes. Concentration of (a, b) cell
associated and (c, d) secreted Angptl4 protein was quantified by ELISA in myotubes derived from six men and incubated in the presence of (a, c)
BSA-bound oleic acid (OA-BSA, 0.5 mM) or (b, d) Insulin (100 nM) for 24 hours. *p,0.05, paired t test compared with Control.
doi:10.1371/journal.pone.0046212.g002
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Gene expression analyses
Angptl4 mRNA levels were measured by real time PCR.
Cultured cells were homogenized in RLT buffer (Qiagen) and
total RNA was isolated with RNeasy Mini kit (Qiagen) according
to the manufacturer’s instructions. The total RNA (2 mg) was
reverse-transcribed using Maxima First Strand cDNA Synthesis
Kit (Fermentas). Samples were amplified on a 7000 Sequence
Detection System (Applied Biosystems), using FastStart Universal
SYBR Green Mastermix with ROX (Roche). Housekeeping genes
used were bActin and PBGD (human) or 36B4 and HPRT
(mouse). Primer sequences are provided in the Table S1.
RNA interference
C2/LPL myoblasts were seeded in 24-well plates and transfect-
ed with siGENOME siRNA set (Dharmacon, Thermo Scientific)
at 25 pmols/well as previously described [11] with minor
modifications. Transfection was achieved using DharmaFECT1
(Dharmacon, Thermo Scientific) and cells were allowed to
differentiate only for 3 days before LPL activity was assayed due
to the transient nature of siRNA silencing.
Figure 3. PPARd activation increases Angptl4 mRNA and protein levels in human and mouse C2/LPL myotubes. (a) Human myotubes
were incubated for 24 hours in the presence of DMSO (Control) or GW501516 (0.1 mM) and Angptl4 concentration in medium and cell lysate was
quantified using ELISA, n = 4. Angptl4 mRNA levels were measured by real time PCR in (b) human and (c) mouse myotubes incubated with DMSO
(Control) or GW501516 (0.1 mM) for 24 hours, n = 4. Angptl4 mRNA levels were normalized and analyzed in parallel with human PBGD and mouse
HRPT mRNA levels. (d) Secretion of Angptl4 from C2/LPL myotubes was analyzed by Western blot 48 hours after incubation with DMSO (Control) or
GW501516 (0.1 mM). Samples from two experiments were loaded on the gel. Right panel shows Ponceau staining of the blotting membrane as a
control for protein loading and efficient transfer from the gradient gel to nitrocellulose membrane. *p,0.05, paired t test compared with Control.
doi:10.1371/journal.pone.0046212.g003
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SDS-PAGE and Immunoblot Analysis
C2/LPL myotubes were differentiated in 12-well plates and
incubated in 0.5 ml serum free medium per well. Conditioned
media were concentrated approximately 100-fold using Nanosep
10k Omega columns (Pall) and equal volumes, corresponding to
200 ml of non-diluted medium, were separated on a NuPAGE 4–
12% Novex Bis-Tris gels (Invitrogen). Proteins were electro-
transferred to nitrocellulose membranes and the transfer quality
Figure 4. PPARd activation by GW501516 inhibits LPL activity and LPL-dependent fatty acid uptake. (a) Heparin releasable LPL activity
was measured in the L6, C2C12 and C2/LPL myotubes after 24 hour incubation of the cells in the presence of GW501516, n = 3. (b) Time dependent
inhibition of LPL activity by GW501516 (0.1 mM) was measured in heparin releasable pool from C2/LPL myotubes, n = 3. (c) Oil Red O staining of
myotubes was quantified by densitometry in cells incubated with Intralipid or OA-BSA for 5 hours in the presence or absence of GW501516, n = 4. (d)
Intracellular triglycerides quantification in cells incubated with Intralipid for 5 hours in the presence or absence of GW501516, n = 3 (e) Fluorescence
microscope images of C2/LPL myotubes (highlighted with a line) incubated with Intralipid for 5 hours in the presence or absence of GW501516.
Nuclei are stained in blue (DAPI) and lipid droplets in red (Oil Red O). * p,0.05, paired t test (a) or One-way ANOVA with Dunnett’s post test (b, c, d)
compared with Control.
doi:10.1371/journal.pone.0046212.g004
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was evaluated by Ponceau red staining. Endogenous mouse
Angptl4 (mAngptl4) secreted from C2/LPL cells was detected
using a purified polyclonal rabbit IgG raised against recombinant
mAngptl4 (AG-25A-0071-C100, Adipogen). As a positive control
we used medium from HEK293 cells transfected with recombi-
nant mAngptl4, using a plasmid kindly provided by Professor
Aimin Xu (University of Hong Kong, China).
LPL Activity
L6 and C2C12 myotubes were differentiated in 10-cm plates
whereas C2/LPL myotubes were differentiated in 6-well, 12-well
or 24-well plates. Plates were transferred on ice, medium was
aspirated and cells were washed three times with cold PBS. LPL
was released from myotubes by incubating the cells with Krebs
Ringer Hepes buffer (130 mM NaCl, 10 mM HEPES, 10 mM
MgSO467H2O, 2.5 mM NaH2PO46H2O, 4.6 mM KCl,
2.5 mM CaCl262H2O, 2.5 mM Na-pyruvate, pH 7.4) containing
100 mg/ml Heparin (KRH-Heparin) for 5 minutes on ice (heparin
releasable LPL). To measure intracellular LPL activity cells were
further washed with PBS and incubated with Trypsin-EDTA
[0.1% (w/v) Trypsin, 50 mM EDTA in PBS, pH 7.4] at room
temperature (RT) for approximately 5 minutes, until cells
detached. Further, cells were transferred back on ice and
Trypsin-EDTA removed by washing twice with cold PBS. The
pellet was centrifuged at 300 g for 3 minutes at +4uC and
sonicated for 10 seconds in KRH-Heparin buffer (intracellular
LPL). Heparin releasable and intracellular LPL activity was
measured as previously described [22] with some modifications.
Briefly, [Carboxyl-14C]-Triolein (S.A. 2.2 GBq/mmol, PerkinEl-
mer) and glyceryl trioleate (Sigma) emulsified in the presence of
gum arabic was used as substrate. KRH-Heparin buffer derived
from myotubes (heparin releasable or intracellular LPL) was
incubated with the substrate and human serum (as a source for
apoC-II, LPL cofactor) for 1 hour at 37uC. Reaction was stopped
by addition of 3.25 ml of methanol-chloroform-heptane
(1.41:1.25:1.00, vol/vol/vol) and 0.75 ml of potassium carbon-
ate/borate buffer (pH 10.5). Hydrophilic phase (BSA-FAs) and
hydrophobic phase (triolein) were separated by centrifugation and
radioactivity was measured from both fractions by liquid
scintillation counting (Wallac LS Counter, Turku, Finland). LPL
activity was expressed as mol of FAs released per hour per mg of
cell protein. To evaluate the effect of purified Angptl4 on LPL
activity we used recombinant hAngptl4 (4487AN, R&D Systems).
Oil Red O staining
To quantify and visualize the intracellular neutral lipids we used
Oil Red O (ORO) staining. Myotubes were differentiated in 6-
well, 12-well or 24-well plates with or without coverslips and
incubated with lipids for 5 (C2/LPL) or 16 (L6) hours. OA-BSA or
Intralipid (Sigma) were added 48 hours after infection or 2 hours
after treatment with the LPL inhibitor Orlistat (Sigma). After
fixation with 10% formalin in PBS myotubes were stained with
0.12% (w/v) ORO in 60% isopropanol. Myotubes were
thoroughly washed, ORO was extracted with 100% isopropanol
and absorbance was measured at 490 nm. Empty wells were used
to measure the blank. For cells grown on coverslips nuclei were
stained with DAPI, mounted and visualized in fluorescence
microscopy using Axioplan 2 Imaging E (Zeiss) microscope.
Triglyceride quantification
To quantify the intracellular triglycerides in C2/LPL myotubes
cells were lysed in RIPA buffer, sonicated and then heated at 95uC
for 10 minutes until samples became cloudy. After the samples
reached room temperature insoluble cell debris was removed by
centrifugation and triglycerides were measured using an enzymatic
colorimetric assay (Cobas, Roche/Hitachi).
Figure 5. Regulation of Angptl4 expression and LPL activity by
bexarotene in C2/LPL myotubes. (a) Secretion of Angptl4 from C2/
LPL myotubes was analyzed by Western blot 48 hours after incubation
with DMSO (Control) or 0.2 mM bexarotene. Samples from two
experiments were loaded on the gel. (b) Angptl4 and LPL mRNA levels
were measured by real time PCR in C2/LPL myotubes incubated with
DMSO (Control) or 0.2 mM bexarotene for 24 hours. Values are
expressed relative to mouse 36B4 mRNA levels. (c) C2/LPL myotubes
untreated or pre-treated overnight with 1 mM GSK0660, a PPARd
antagonist, were incubated with DMSO (Control) or 0.2 mM bexarotene
for 4 hours. Heparin releasable LPL activity was measured and
normalized to the protein content. * p,0.05, Two-way ANOVA with
Bonferroni post-tests.
doi:10.1371/journal.pone.0046212.g005
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Fluorescence microscopy
C2/LPL myoblasts seeded on coverslips were fixed with 4%
paraformaldehyde, PBS, pH 7.4 for 20 min at RT. Permeabilisa-
tion and blocking was performed with 10% heat inactivated FBS
in PBS with 0.1% Triton X-100 for 1 hour at RT. The coverslips
were incubated with primary antibodies in blocking buffer at 4uC,
overnight. Coverslips were washed 365 min with PBS, 0.1% Tx-
100 to remove unbound antibodies and incubated with the
secondary antibodies (Alexa 549- or Alexa 633-labelled goat anti
chicken) diluted 1:200 in blocking buffer for 1 hour at RT. After
washing 365 min with PBS, 0.1% Tx-100, the specimens were
mounted in ProLong Gold (Invitrogen) and analyzed using a Leica
TCS SP2 laser scanning confocal microscope system. LPL was
detected using an immunopurified chicken antibody against LPL
(a gift from Professor Gunilla Olivecrona, Umea¨, Sweden) diluted
at 7 mg/ml with blocking buffer. For co-localization studies C2/
LPL myoblasts were transfected with human Angptl4 using a
plasmid kindly provided by Professor Sander Kersten (Wagenin-
gen University, The Netherlands) and Lipofectamine 2000
(Invitrogen). After immunostaining for LPL, Angptl4 was detected
with an anti-V5 Mouse mAb, FITC Conjugate (Invitrogen) diluted
1:500 in blocking buffer for 1 hour at RT. The specificity of the
antibodies was tested using mock transfected cells (for Angptl4) or
by pre-incubating the antibodies with bovine LPL (for LPL).
Fatty acid oxidation
L6 myotubes were differentiated in 6-well or 12-well plates and
FA oxidation was measured using [1-14C]-Palmitic acid (S.A.
2 GBq/mmol, ARC 0172A, ARC) or [9,10-3H(N)]-Palmitic acid
(S.A. 1.5 TBq/mmol, ART 0129, ARC) 72 hours post-infection.
[1-14C]-Palmitic acid oxidation to 14C-CO2 and
14C-Acids soluble
metabolites (ASM) was measured as previously described [23] with
some modifications. Briefly, cells were incubated with 0.4 mCi per
well (1 ml) of BSA-bound palmitic acid in serum free DMEM
(5 mM glucose) for 90 minutes. Medium (750 ml) was transferred
in 2 ml tubes containing 150 ml 70% percloric acid and having
Whatman paper soaked in 30 ml 5N NaOH placed in the caps.
Caps were closed quickly avoiding contamination of the Whatman
paper with radioactive medium. The CO2 was released from the
media and trapped on the Whatman paper by incubating the
tubes for 90 minutes at 37uC. [9,10-3H(N)]-Palmitic acid oxida-
tion to 3H-H2O was measured as previously described [24] after
four hours of incubation in the presence or absence of GW501516.
Labeled CO2, ASM and H2O were measured by liquid
Figure 6. Angptl4 inhibits LPL activity and LPL-dependent fatty acid uptake and mediates PPARd effect on LPL activity. (a) Human
Angptl4 concentration was evaluated by ELISA in medium from myotubes infected with HSA (human serum albumin)-AAV2 (Control) or hAngptl4-
AAV2. (b) Heparin releasable LPL activity was measured in myotubes infected with HSA-AAV2 (Control) or hAngptl4-AAV2, n = 4 for L6 and n= 3 for
C2/LPL. LPL activity expressed as 100% represent 0.037 (L6) or 3.38 (C2/LPL) mmol FAs h21 mg21. (c) Heparin releasable LPL activity was measured in
C2/LPL myotubes exposed to increasing concentration of recombinant hAngptl4. LPL activity expressed as 100% represent 2.58 mmol FAs h21 mg21.
(d) Myotubes infected with HSA-AAV2 or Angptl4-AAV2 or treated with Orlistat (50 mM) were incubated 16 h with Intralipid or OA-BSA. Oil Red O
staining of myotubes was quantified by densitometry, n = 4. (e) Cells transfected with non targeting siRNA (NT-siRNA) or Angptl4 siRNA were
incubated with GW501516 for 4 hours and heparin releasable LPL activity was quantified, n = 3. * p,0.05, paired t test (b) or Two-way ANOVA with
Bonferroni post-tests (d, e) compared with Control.
doi:10.1371/journal.pone.0046212.g006
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scintillation counting (Wallac LS Counter, Turku, Finland) and
values expressed as mmol of FA oxidized per minute per mg of cell
protein.
Glucose uptake, glycogen synthesis and glucose
oxidation
L6 myotubes were differentiated in 12-well plates and analyzed
72 hours post-infection. Glucose uptake was measured using 2-
[1,2-3H(N)]-Deoxy-D-glucose (2DG, S.A. 250 GBq/mmol, NE-
T328A001MC, Perkin Elmer) as described previously [25].
Glycogen synthesis and glucose oxidation were measured in the
same experiments using D-[14C(U)]-Glucose (S.A. 10 GBq/mmol,
ARC 0122H, ARC) in 5 mM glucose DMEM. Incorporation of
glucose into glycogen was measured after isolation of glycogen as
described previously [17]. Oxidation of glucose to CO2 was
measure by adapting the protocol described for palmitate
oxidation [23]. Briefly, cells were incubated cells were incubated
with 0.5 mCi per well (0.5 ml) of D-[14C(U)]-Glucose in serum free
DMEM (5 mM glucose) for 90 minutes. Medium (400 ml) was
transferred in 2 ml tubes containing 75 ml 70% percloric acid and
having Whatman paper soaked in 30 ml 5N NaOH placed in the
caps. Caps were closed quickly and the CO2 was released from the
media and trapped on the Whatman paper by incubating the
tubes for 90 minutes at 37uC. Radioactivity was measured by
liquid scintillation counting (Wallac LS Counter, Turku, Finland)
and values were expressed as pmol of glucose per minute per mg of
cell protein.
Statistical analyses
Values from at least 3 experiments are reported as mean 6
SEM and statistical significance was determined using paired t test
or One- or Two-way ANOVA, as specified in each figure. Values
of p,0.05 were considered as significant. Statistical analyses were
performed using GraphPad Prism for Windows, GraphPad
Software, San Diego California USA, www.graphpad.com.
Results
Angptl4 mRNA and protein levels are increased during
differentiation of myotubes
To study the Angptl4 expression during differentiation of
myoblasts into myotubes we used human (Fig. 1a, b) and mouse
C2/LPL (Fig. 1d, e) cells. Proliferative myoblasts (Fig. 1a, d) were
differentiated for seven days to form multinucleated myotubes
(Fig. 1b, e). A progressive increase of Angptl4 secretion during
differentiation of human cells was observed (Fig. 1c). This is
supported by a significant increase of Angptl4 mRNA levels on
day 5 and 7 when compared with day 2 of differentiation, whereas
PBGD mRNA levels remained unchanged (Fig. S1). In mouse
C2/LPL cells we observed an increase of Angptl4 mRNA levels
during the first three days of differentiation before reaching a
plateau level on day four. In contrast, the mRNA levels of Ppard
(Fig. 1f) and the housekeeping gene, HPRT, (data not shown) were
not changed during the differentiation process. Secretion of
Angptl4 from mouse cells could not be measured by Western blot
due to very low protein levels and presence of serum in the
differentiation medium.
Regulation of Angptl4 expression in myotubes
In order to study the regulation of hAngptl4 by OA-BSA and
insulin we used fully differentiated myotubes derived from six
healthy men. An increase in cell associated (Fig. 2a, b) and secreted
Figure 7. Angptl4 inhibits intracellular LPL activity and co-
localizes with intracellular LPL. (a) Heparin releasable and
intracellular LPL activity was measured in C2/LPL myotubes incubated
with GW501516 (0.1 mM) for 24 hours, n = 3. (b, c, d) Confocal
microscopy of myoblasts transfected with V5 tagged Angptl4 and
stained with antibodies against LPL (b) and V5 tag (c). Scale bar: 20 mm.
* p,0.05, paired t test.
doi:10.1371/journal.pone.0046212.g007
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Angptl4 (Fig. 2c, d) was observed when myotubes were incubated
in the presence of OA-BSA or insulin for 24 hours.
Using GW501516, a synthetic PPARd agonist, we obtained a
similar induction of Angptl4 expression in human myotubes as
observed with OA-BSA (Fig. 3a). Treatment of myotubes with
GW501516 for 24 hours induced a robust increase in Angptl4
mRNA levels in both human and mouse C2/LPL cells (Fig. 3b
and c respectively). Secretion of endogenous mAngptl4 was
detected by Western blot only from C2/LPL cells stimulated with
GW501516 (Fig. 3d). Using an antibody that recognizes all 3
forms of mAngptl4 we were able to detect the full-length, C-
terminal, and N-terminal fragments of both endogenous and
overexpressed protein (Fig. 3d).
PPARd activation inhibits LPL activity and LPL-dependent
fatty acid uptake
We further evaluated if activation of PPARd by GW501516
modulates LPL activity in myotubes. L6, C2C12, and C2/LPL
myotubes incubated with GW501516 for 24 hours had a
significantly lower heparin releasable LPL activity compared with
DMSO treated cells (Fig. 4a). Using our methods LPL activity
could not be measured in human myotubes. To determine the
time dependency of GW501516-mediated LPL inhibition, we
incubated C2/LPL cells up to 24 hours and measured the heparin
releasable LPL activity. As shown in Fig. 4b LPL activity was
decreased by 50% already after 3 hours incubation with
GW501516. GW501516 treatment of C2/LPL cells robustly
increased Angptl4 mRNA levels already at 1 hour of treatment
but had no effect on human LPL mRNA levels, or directly on LPL
activity as measured in human post-heparin plasma incubated for
one hour with 50 mM GW501516 (Fig. S2 a and b, respectively).
Preincubation of C2/LPL myotubes with GW501516 for 20 hours
blocked the cellular FA uptake during incubation with Intralipid as
measured by Oil Red O staining of the myotubes and as verified
by triglyceride quantification in cell lysates (Fig. 4c, d, e) but had
no effect on the uptake of OA-BSA (Fig. 4d).
Figure 8. Angptl4 overexpression has no effect on fatty acids oxidation and glucose metabolism in L6 myotubes. Fatty acid
(palmitate) oxidation was evaluated by measuring (a) 14C-CO2 or (b)
14C-acid soluble metabolites (14C-ASM) production in L6 myotubes 72 hours
post-infection with HSA-AAV2 (Control) or Angptl4-AAV2 and compared with cells incubated with DMSO (Control) or GW501516 for 24 hours, n = 3.
(c) Palmitate oxidation was evaluated by measuring 3H-H2O released from myotubes incubated with low doses of GW501516 in the setting of low
(HSA-AAV2) and high (Angptl4-AAV2) Angptl4 levels, n = 4. (d) Glucose uptake, (e) glycogen synthesis and (f) glucose oxidation were measured in L6
myotubes 72 hours post-infection with HSA-AAV2 or Angptl4-AAV2 in the absence (Basal) or presence of insulin (100 nM), n = 3. *p,0.05, One-way
(a, b) or Two-way (c–f) ANOVA with Bonferroni post-tests.
doi:10.1371/journal.pone.0046212.g008
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RXR activation increases Angptl4 expression and inhibits
LPL activity in C2/LPL myotubes
Because PPARd exerts its function by forming an obligatory
heterodimer with retinoic X receptor (RXR) we evaluated whether
RXR activation by bexarotene has similar effect compared with
that of GW501516 on Angptl4 expression and LPL activity.
Indeed, treatment of C2/LPL myotubes with bexarotene strongly
induced Angptl4 mRNA and protein levels without significant
changes in LPL expression levels as evaluated by real time PCR
(Fig. 5a, b). Similarly to GW501516, bexarotene significantly
inhibited heparin releasable LPL activity after 4 hours treatment
of C2/LPL cells (Fig. 5c). Inhibition of LPL activity by
pharmacological activation of RXR was dependent on PPARd
function since incubation of C2/LPL cells with a PPARd
antagonist, GSK0660, completely blocked the bexarotene effect
(Fig. 5c).
Angptl4 mediates PPARd/RXR effect on LPL activity and
LPL-dependent fatty acid uptake
The direct role of Angptl4 in mediating LPL inhibition by
GW501516 and bexarotene was verified using AAV2 and AAV9
encoding hAngptl4, as well as using recombinant hAngptl4 and
siRNA targeted silencing. AAV9 delivery of hAngptl4 in mice was
performed as described in Methods S1 and resulted in the
appearance of hAngptl4 in serum (Fig. S3a) and a concomitant
increase in plasma triglycerides (Fig. S3b) when compared with the
AAV9 delivery of HSA. Following the Angptl4-AAV2 transduc-
tion, the levels of secreted hAngptl4 were moderate in L6
myotubes and very low in C2/LPL myotubes (Fig. 6a). Overex-
pression of hAngptl4 inhibited LPL activity in both L6 and C2/
LPL myotubes when compared with HSA-AAV2 transduced cells
(Fig. 6b). When the C2/LPL myotubes were incubated four hours
with full length recombinant hAngptl4 we observed a concentra-
tion dependent inhibition of LPL activity by hAngptl4 (Fig. 6c).
Human Angptl4 or Orlistat (a lipase inhibitor) blocked the LPL-
dependent uptake of FAs from Intralipid but had no effect on the
uptake of OA-BSA (Fig. 6d). Furthermore, silencing of Angplt4
gene with specific siRNA abolished the inhibitory effect of
GW501516 and bexarotene on LPL activity in C2/LPL myotubes
(Fig. 6e, see also Fig. S4 for silencing efficiency).
Angptl4 inhibits intracellular LPL activity and co-localizes
with LPL
Because Angptl4 and LPL are produced in the same cells we
evaluated inhibition of LPL activity and co-localization of these
two factors intracellularly. Although GW501516 treatment inhib-
ited LPL activity mainly in the heparin releasable pool a significant
inhibition of LPL activity was also observed intracellularly (Fig. 7a).
Intracellular localization of LPL (Fig. 7b) and Angptl4 (Fig. 7c) was
confirmed using confocal microscopy. Overlaying of the immu-
nostaining patterns revealed an extensive intracellular co-localiza-
tion between Angptl4 and LPL (Fig. 7d). The specificity of the
antibodies against V5 epitope and LPL was demonstrated using
mock transfected cells or via competition approach by pre-
incubation of the antibody with exogenous LPL (Fig. S5).
Angptl4 has no effect on fatty acid oxidation and glucose
metabolism
Using L6 myotubes we evaluated the role of Angptl4 in the
regulation of FA oxidation and glucose metabolism. In contrast to
GW501516, Angptl4 overexpression had no effect on palmitate
oxidation as verified by 14C-CO2 and
14C-ASM production
(Fig. 8a, b). Furthermore, Angptl4 did not change basal and
GW501516-induced palmitate oxidation to 3H-H2O (Fig. 8c).
Figure 9. Proposed mechanism regulating LPL activity in the skeletal muscle. The working hypothesis is that FAs produced locally by LPL-
mediated hydrolysis of VLDL and chylomicrons (CM) together with FAs derived from adipose tissue (FA-albumin) can activate PPARd/RXR
heterodimer which in turn upregulates Angptl4 gene expression. Angptl4 inhibits LPL activity mainly at the surface of the sarcolemma where less LPL
will be available to be transported at luminal sites via the function of GPIHBP1. LPL inhibition by Angptl4 occurs to a lesser extent also intracellularly.
This mechanism may protect the skeletal muscle from lipid overload and insulin resistance but may also contribute to bexarotene induced systemic
hypertriglyceridemia.
doi:10.1371/journal.pone.0046212.g009
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Angptl4 overexpression had no effect on basal and insulin
stimulated glucose uptake, oxidation and incorporation into
glycogen (Fig. 8d, e, f).
Discussion
In the present study we have demonstrated that activation of
PPARd/RXR strongly upregulates Angptl4 causing the inhibition
of LPL activity and LPL-dependent FA uptake in myotubes. In
addition, we have examined the role of Angptl4 in fatty acid
oxidation and glucose metabolism.
It was recently reported that in skeletal muscle cells the gene
with the highest fold-induction by FAs is Angptl4 and this effect is
mediated by PPARd [11]. Here we confirm a robust increase of
Angptl4 by FAs or GW501516, a specific PPARd activator [26], in
both human and mouse myotubes. Processing of endogenous
Angptl4 in myotubes showed a similar pattern with that observed
in HEK293 or Huh7 cells overexpressing Angptl4 [21,27], the full
length, C-terminal and N-terminal forms being secreted from C2/
LPL myotubes treated with GW501516. Angptl4 is a well
established LPL inhibitor [12,13] suggesting that PPARd activa-
tion by FAs can inhibit LPL activity in myotubes. Indeed,
treatment of rat and mouse myotubes with GW501516 induced a
significant reduction in heparin releasable LPL activity without
significant changes in LPL mRNA levels. Kinetic studies in C2/
LPL cells showed a robust upregulation of Angptl4 expression
already at 1 hour and a 50% reduction of LPL activity at 3 hours
after the start of GW501516 treatment. Consequently, the uptake
of FAs from Intralipid, which is dependent of LPL activity, was
abolished by GW501516. In contrast, the uptake of free fatty acids
was not affected by GW501516. Inhibition of LPL activity by
PPARd activation was dependent on Angptl4 mRNA expression
since Angptl4 silencing using siRNA blocked the GW501516
effect. Previous studies have shown that in skeletal muscle LPL
overexpression increases intracellular triglyceride-pool [28] where-
as LPL deletion decreases intracellular triglycerides stores [29].
The LPL-mediated effect on lipid uptake has consequences on
insulin signaling cascade in skeletal muscle [28,29]. Since LPL
activity generates FAs, it is possible that activation of the PPARd-
Angptl4 axis functions as a negative feedback mechanism that may
serve to protect the muscle fibers from lipid overload (Fig. 7). The
mechanism we suggest here is also relevant in vivo, i.e. data
provided by Tanaka et al. [6] demonstrate that administration of
GW501516 to mice fed a high-fat diet markedly reduced the lipid
droplet formation in skeletal muscle [6]. The same mechanism was
recently described to protect the heart and macrophages from
lipotoxicity in mice fed a high-fat diet [30,31].
In order to regulate gene expression PPARd forms an obligatory
heterodimer with RXR [32]. Bexarotene is a potent and selective
RXR agonist that is currently used in the treatment of cutaneous
T cell lymphoma and has promising effects in other forms of
cancer or dermatologic disorders but its use in clinics is limited due
to its undesirable increase effect on plasma triglycerides [33]. The
mechanism underlying this side effect is not completely under-
stood. Interestingly, a study performed in rats suggests that
bexarotene-induced hypertriglyceridemia is attributable to inhibi-
tion of LPL activity in the muscle [34]. This is further supported
by the increased skeletal muscle lipoprotein lipase activity observed
in RXRc deficient mice [35]. Here we found that in myotubes the
inhibition of LPL activity by bexarotene is dependent on PPARd
and Angptl4. Upregulation of Angptl4 expression by bexarotene is
in agreement with previous observations in thyroid cancer cell
lines [36]. These data suggest a mechanism that could contribute
to increased triglycerides in patients during bexarotene therapy.
Population studies suggest that Angptl4 is not involved in
systemic inhibition of LPL in humans [21,37]. Since Angptl4 is the
only known LPL inhibitor expressed in the same cells where LPL
is produced, it is conceivable that it has more subtle roles at the
tissue level. Overexpression of Angptl4 in myotubes resembles the
GW501516 effect on LPL activity and LPL-dependent FA uptake.
Angptl4 acts in a concentration dependent manner and interest-
ingly, it appears more effective when expressed together with LPL
within the same cells than when added as a recombinant protein.
A weaker effect of Angptl4 on LPL activity was also seen in cells
treated with conditioned medium from myotubes overexpressing
Angptl4 (data not shown). This phenomenon can be explained by
our observation that Angptl4 inhibited LPL activity not only at the
cell surface, represented by the heparin releasable pool, but also
intracellularly. Moreover, confocal microscopy analysis revealed
extensive intracellular co-localization of LPL and Angptl4 in
reticular perinuclear-concentrated ER membranes. All these
observations suggest that LPL and Angptl4 could interact
intracellularly making the inhibition more efficient when both
proteins are expressed within the same cell. The inhibition of LPL
by Angptl4 occurs before GPIHBP1 interaction with LPL and its
transport to the luminal site of the capillary endothelium [3,4].
This notion is physiologically relevant since GPIHBP1 was shown
to prevent LPL inhibition by Angptl4 [38]. Interestingly, insulin
increases Angptl4 expression in myotubes which is in contrast with
adipocytes where insulin downregulates Angptl4 mRNA expres-
sion [39]. All these data suggest that Angptl4 could be implicated
in the tissue specific regulation of LPL activity by insulin [40,41].
PPARd overexpression or activation by GW501516 increased
the catabolism of FAs by upregulation of genes implicated in FA
uptake, handling, and mitochondrial import in skeletal muscle [5–
10]. Because Angptl4 is a multifunctional protein we tested
whether it plays a role in fatty acid (palmitate) oxidation. As
expected, PPARd activation increased 14C-CO2 and
14C-ASM
production by L6 myotubes, however, Angptl4 overexpression had
no effect on the b-oxidation. We confirmed this by using 3H-
palmitic acid and quantification of the 3H-H2O produced by L6
myotubes overexpressing Angptl4. Angptl4 was suggested to
upregulate lipolytic enzymes such as hormone sensitive lipase in
C2C12 myocytes [11] and therefore we tested wheather Angptl4
could enhance the oxidative capacity of GW501516. Using a low
dose of GW501516 we observed a similar induction of palmitate
oxidation in control and Angptl4 overexpressing L6 myotubes.
These data strongly suggest that the induction of FA oxidation by
PPARd is not dependent on extra- or intracellular Angptl4.
Previous studies have shown that Angptl4 significantly de-
creased hepatic glucose production and enhanced insulin-mediat-
ed inhibition of gluconeogenesis suggesting a role of Angptl4 in
glucose metabolism [42]. In our study, Angptl4 overexpression in
L6 myotubes neither affected glucose uptake, glycogen synthesis
and glucose oxidation, nor insulin function in regulating these
processes. These results suggest a tissue specific regulation of
glucose metabolism by Angptl4.
A limitation to consider in our study is that we used cultured
myotubes and this system lacks the endothelial cell layer where
LPL exerts its function in vivo. Because Angptl4 and LPL are
produced in the same cells it is relevant that their interaction
should occur before LPL reaches endothelial cells. For this
purpose myotubes provide a relevant model to study the
mechanism of LPL inhibition by Angptl4 in contrast to liver
derived inhibitors that probably act mainly at the luminal surface
of the capillary endothelium.
In conclusion, our principal results suggest that an overflow of
FAs inhibits LPL activity in skeletal muscle. The working
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hypothesis is that FAs produced locally via the LPL function or
released from adipose tissue as albumin bound FAs can activate
PPARd/RXR heterodimer which in turn upregulates Angptl4
gene expression. Angptl4 inhibits LPL activity mainly at the
surface of the sarcolemma where less LPL will be available to be
transported at luminal sites via the function of GPIHBP1 and
therefore the flow of FAs in the tissue is reduced (Fig. 9). This
mechanism may also contribute to increased plasma triglycerides
frequently observed in patients treated with bexarotene. In
addition, PPARd increases the FA oxidation capacity of the tissue
independently of Angptl4. All these suggest PPARd as being a key
player in maintaining the balance between the FA uptake and
oxidation capacity of the skeletal muscle.
Supporting Information
Figure S1 Angptl4 mRNA during differentiation of
human myotubes. Angptl4 and PBGD mRNA levels were
measured by real time PCR on day 2, 5 and 7 of differentiation in
myoblasts derived from four men. Values are expressed as fold
increase relative to day two of differentiation and normalized to
human bActin mRNA levels, mean6SEM, n= 4. * p,0.05,
Student’s t test.
(PDF)
Figure S2 Effect of GW501516 on Angptl4 and LPL
mRNA in C2/LPL cells and LPL activity in human post
heparin plasma. (a) Angptl4 and LPL mRNA levels were
measured by real time PCR in C2/LPL myotubes incubated with
DMSO (Control) or GW501516 (0.1 mM) for 1–4 hours. Values
were normalized to m36B4 levels and expressed as mean 6 SEM,
n=3. (b) LPL activity was measured in human post-heparin
plasma was incubated with DMSO or GW501516 (50 mM) for
1 hour at RT. * p,0.05, Student’s t test.
(PDF)
Figure S3 Mice were injected with HSA-AAV9 (n=3) or
Angptl4-AAV9 (n=3) into tibialis anterior muscles and
intraperitoneally. Two weeks after injections plasma (a)
Angptl4 levels and (b) triglycerides were measured by ELISA
and enzymatic colorimetric assay respectively. Values are
expressed as mean 6 SEM of 3 animals per group. * p,0.05,
Student’s t test.
(PDF)
Figure S4 Efficiency of mAngptl4 gene silencing in C2/
LPL cells. Mouse Angptl4 mRNA levels were measured by real
time PCR in C2/LPL myotubes transfected with non targeting
siRNA (NT-siRNA) or Angptl4 siRNA. Values are normalized to
HPRT and expressed as mean 6 SEM, n= 3.
(PDF)
Figure S5 Specificity of Angptl4 and LPL immunostain-
ings. C2/LPL myoblasts were either transfected with the empty
vector (mock, a) or with Angptl4-V5 (Angptl4, b) and immuno-
stained using anti-V5 mAb, FITC Conjugate. Cells were stained
with anti-LPL immunopurified IgY that was either preincubated
with bovine LPL (+ bovine LPL, c) or without bovine LPL (2
bovine LPL, d). DAPI was used to stain the nuclei (blue). Wide-
field fluorescence images were acquired with using Axioplan 2
Imaging E (Zeiss) microscope. Scale bar: 50 mm.
(PDF)
Table S1 Primers utilized for Real Time PCR.
(DOCX)
Methods S1 Supplementary methods for experiments
performed in mice.
(DOCX)
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